Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2-mutated cholangiocarcinoma and IDH1-mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH-mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.
Authors
- Tomoya Yokota (ORCID: https://orcid.org/0000-0001-7327-7949)
- Li‐Yuan Bai (ORCID: https://orcid.org/0000-0001-7739-4077)
- Wei Peng Yong (ORCID: https://orcid.org/0000-0003-4404-3777)
- Rachna T. Shroff (ORCID: https://orcid.org/0000-0003-0066-2672)
- Anthony B. El-Khoueiry (ORCID: https://orcid.org/0000-0002-9053-3841)
- David B. Radtke (ORCID: https://orcid.org/0009-0005-5103-5013)
- Mitesh J. Borad (ORCID: https://orcid.org/0000-0003-2700-2658)
- Ivelina Gueorguieva (ORCID: https://orcid.org/0000-0001-5864-8924)
- Kyriakos P. Papadopoulos (ORCID: https://orcid.org/0000-0002-0667-2620)
- Masafumi Ikeda (ORCID: https://orcid.org/0000-0002-4050-2086)
- Kurt A. Jaeckle (ORCID: https://orcid.org/0000-0002-7827-463X)
- Anita Turk (ORCID: https://orcid.org/0000-0002-4159-5376)
- Jordi Rodón (ORCID: https://orcid.org/0000-0001-6467-3632)
- Sani H. Kizilbash (ORCID: https://orcid.org/0000-0001-8568-1519)
- Herbert H. Loong (ORCID: https://orcid.org/0000-0002-6607-1106)
- Rasha Cosman (ORCID: https://orcid.org/0000-0002-4746-0747)
- Lola‐Jade Palmieri (ORCID: https://orcid.org/0000-0002-8540-9344)
- Andreas Varkaris (ORCID: https://orcid.org/0000-0001-5776-8844)
- Anna M. Szpurka (ORCID: https://orcid.org/0000-0002-1348-955X)
- Mark H. Bender (ORCID: https://orcid.org/0009-0006-7918-4229)
- Xiangyuan Xu (ORCID: https://orcid.org/0009-0002-3165-566X)
- Joon Oh Park (ORCID: https://orcid.org/0000-0001-6502-2612)
- Makoto Ueno (ORCID: https://orcid.org/0000-0003-4480-0029)
- Jorge Adeva (ORCID: https://orcid.org/0000-0002-3959-4120)
- Taroh Satoh (ORCID: https://orcid.org/0000-0002-4615-2638)
- Lipika Goyal (ORCID: https://orcid.org/0000-0002-9777-6221)
- Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
- Nilofer S. Azad (ORCID: https://orcid.org/0000-0002-9613-3988)
- James J. Harding (ORCID: https://orcid.org/0000-0002-7029-4310)
- Hsiao-Rong Chen (ORCID: https://orcid.org/0000-0002-7772-5128)
- Chih‐Yi Liao (ORCID: https://orcid.org/0000-0002-5114-3162)
- Shunsuke Kondo (ORCID: https://orcid.org/0000-0001-9565-117X)
- Hui Liu (ORCID: https://orcid.org/0009-0005-2251-0639)
- Teresa Macarulla (ORCID: https://orcid.org/0000-0002-5856-4082)
- Antoine Hollebecque (ORCID: https://orcid.org/0000-0003-2869-7551)
- Li‐Tzong Chen (ORCID: https://orcid.org/0000-0003-3250-7167)
- Sunoj Chacko Varughese (ORCID: https://orcid.org/0009-0008-8639-3496)
- Deepa Sachdeva (ORCID: https://orcid.org/0009-0004-2137-1844)
Institutions
- University of Southern California (US)
- Hebron University (PS)
- Indiana University Health (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Arizona (US)
- Seoul National University (KR)
- Johns Hopkins University (US)
- Kaohsiung Medical University (TW)
- Eli Lilly (United States) (US)
- Palo Alto University (US)
- Chinese University of Hong Kong (HK)
- China Medical University (TW)
- Cornell University (US)
- Institut Gustave Roussy (FR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Kanagawa Prefectural Hospital Organization (JP)
- University of Chicago (US)
- St Vincent's Hospital Sydney (AU)
- National Cancer Centre Japan (JP)
- University of Chicago Medical Center (US)
- Massachusetts General Hospital (US)
- Shizuoka Cancer Center (JP)
- Eli Lilly (United Kingdom) (GB)
- Hospital Universitario 12 De Octubre (ES)
- National University Cancer Institute, Singapore (SG)
- Indiana Cancer Consortium (US)
- Eli Lilly (India) (IN)
- USC Norris Comprehensive Cancer Center (US)
- South Texas Accelerated Research Therapeutics (US)
- Mayo Clinic in Arizona (US)
- China Medical University Hospital (TW)
- Vall d'Hebron Hospital Universitari (ES)
- Loxo Oncology at Lilly (United States) (US)
- Institut Bergonié (FR)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Tokyo Women's Medical University (JP)
- Stanford Medicine (US)
- National Cancer Center Hospital East (JP)
- National University Hospital (SG)
- Mayo Clinic in Florida (US)
- Center for Cancer Research (US)
- The Kinghorn Cancer Centre (AU)
- Texas Center for Infectious Disease (US)
- Osaka University Hospital (JP)
- Tokyo National Hospital (JP)
- Nemours Children's Clinic (US)
- National Cheng Kung University Hospital (TW)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Kanagawa Cancer Center
- Vall d'Hebron Institute of Oncology (ES)
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
- Indiana University – Purdue University Indianapolis (US)
- Sungkyunkwan University (KR)
- Stanford University (US)
- The University of Osaka (JP)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-09-30
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0174
- Citations
- 4
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 8.03